Company / EPS (Diluted)
Relay Therapeutics, Inc. EPS (Diluted) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.79
FY2025
5-year range
-$21.82 / -$2.59
FY2021-FY2025
Trend
-7.7%
vs FY2024
Sector context
#146 of 204
Health Care
What the data says
At $-2.79, Relay Therapeutics, Inc.'s eps (diluted) ranks #146 of 204 in the Health Care sector. Improved from $-3.82 to $-2.79 over the past 2 years.
Based on SEC 10-K filings.
-2.79 in FY2025.
Improved from $-3.82 to $-2.79 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#146 of 204 in Health CareTop 72% of 204This company -$2.79 Sector average -$0.98
▼
-184.8% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 7.7% year-over-year.
- Ranks #146 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2024.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.79 | -7.7% |
| FY2024 | -$2.59 | +32.2% |
| FY2023 | -$3.82 | +29.3% |
| FY2022 | -$5.40 | +75.3% |
| FY2021 | -$21.82 | +0.0% |
| FY2020 | -$21.82 | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026